On February 8, 2025, 4D Molecular Therapeutics announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial, evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. The results were presented at Angiogenesis, Exudation, and Degeneration 2025.
The planned Phase 3 dose of 4D-150 (3E10 vg/eye) demonstrated an 83% reduction in injection burden, with patients requiring a mean of 0.97 supplemental injections over 52 weeks compared to 6.0 injections projected with on-label aflibercept 2 mg administered every eight weeks. In the recently diagnosed subgroup, 87% of patients required 0-1 supplemental injection, and 80% were injection-free through 52 weeks.
The data also highlighted the long-term durability of aflibercept expression for up to two years and a favorable safety profile, with 4D-150 continuing to be well tolerated during up to three years of follow-up. No 4D-150-related hypotony, endophthalmitis, vasculitis, or choroidal effusions have been observed to date, supporting the therapy's potential as a backbone treatment for vascular retinal diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.